The largest Indian drug major, Ranbaxy has a reason to cheer. The US Department of Justice has withdrawn a motion against Ranbaxy Laboratories. The department had filed a case against the drug major over the quality of some drugs produced at the Indian plants of company. The department also alleged the drug major and its US consultant Parexel Consulting for concealing and forging the crucial data. The FDA had also banned 28 drugs of company before three weeks.

Ranbaxy Laboratories submitted a comprehensive set of audit documents to the concerned authorities. It maintained that its pharmaceutical products are safe and effective and it is always committed to work under the rules and regulations of US. It would also ensure to full fill all requirements and standard set by US health department. The company submitted a full detailed-draft about Toansa plant and active pharmaceutical ingredient (API) facilities of Panota Sahib before the court.

The shares of Ranbaxy jumped to 8.32 per cent on the Bombay Stock Exchange (BSE) after this new sand closed at Rs 277.30. Meanwhile, the Japanese drug maker, Daiichi Sankyo said that the company would go for its original deal signed in June this year.